PRESIDENT HAS SERVED AS A REVIEWER FOR THE ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) STUDY SECTION FOR THE NIH

PDX Pharma’s President has served as a reviewer for the ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) Study Section for the National Institute of Health (NIH) held on June 28, 2017.

pdx news

  • PDX Pharmaceuticals Secures Additional Investment from the Kuni Foundation to Advance New Cancer-Fighting Precision Therapies

    2/9/2021
    read more

  • PDX Pharmaceuticals filed international patent applications (PCT) on cancer immunotherapeutics and a provisional application on COVID-19 vaccine

    7/17/2020
    read more

  • Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials

    6/30/2020
    read more

Copyright © 2017 PDX Pharmaceuticals, Inc. All rights reserved